Florina

Quick links to important sections

Florina

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Florina

Property Description
Active Ingredients Ethinyl Estradiol and Levonorgestrel
Form Oral Tablet
Pharmacological Class Hormonal Contraceptive (Combined)
Common Use Prevention of Pregnancy (Contraception)
Origin Synthetic Hormones

What Type of Medication is Florina?

Florina is a Combined Oral Contraceptive (COC), a class of medication specifically used for contraception, which is the prevention of pregnancy. This pharmaceutical preparation is categorized within the high-level pharmacological class of Hormonal Contraceptives. The classification of such hormonal agents is clinically recognized for its reliable approach to female reproductive cycle management. Florina is supplied as an oral tablet and requires a prescription, underscoring its status as a controlled hormonal agent intended for systemic use via the oral route.

Composition: Ethinyl Estradiol and Levonorgestrel

The core composition of Florina relies on a fixed-dose combination of two synthetic steroid hormones: Ethinyl Estradiol (the synthetic estrogen component) and Levonorgestrel (the synthetic progestin component). Levonorgestrel and Ethinyl Estradiol are reliable, widely used active ingredients in global contraceptive programs. The established use of this dual-hormone blend has been the subject of extensive pharmacological studies, confirming the synergistic action required for high-level efficacy in family planning. The synthetic origin of both active ingredients ensures consistent formulation characteristics within the oral tablet structure.

The General Purpose of Florina

The fundamental and essential therapeutic use of Florina is the reliable prevention of pregnancy in women of reproductive potential. This objective is achieved through a multi-faceted physiological action that creates conditions hostile to conception. Its primary mechanism is the inhibition of ovulation (stopping the release of an egg), which is supported by secondary effects such as increasing the thickness of cervical mucus to block sperm and altering the endometrial lining to discourage implantation. These combined actions define the medicine's overarching benefit as a robust, systemic tool for effective hormonal birth control.

What side effects are possible with Florina?

Possible Side Effects and Safety Information for Florina

The official safety profile for Florina, a combined oral contraceptive containing Ethinyl Estradiol and Levonorgestrel, is defined by regulatory bodies through specific categories of adverse reactions and safety limitations.

Commonly Documented Adverse Reactions

Adverse effects listed as common or very common in regulatory labeling often relate to several body systems:

  • Nervous and Psychiatric Systems: Headache, including migraines, and mood changes such as depression.
  • Gastrointestinal System: Nausea, vomiting, and abdominal pain.
  • Reproductive System: Breast tenderness or pain, and irregular uterine bleeding (spotting or breakthrough bleeding).
  • Other: Weight gain and acne.

Serious Adverse Reactions and Vascular Risk

The most serious safety concerns documented in regulatory prescribing information are Thromboembolic Events. These include the risk of Venous Thromboembolism (VTE), such as deep vein thrombosis and pulmonary embolism, and Arterial Thromboembolism (ATE), leading to events like myocardial infarction or stroke. Other serious documented reactions include significant Hypertension, Gallbladder Disease, and the potential for Benign or Malignant Liver Tumors.

Regulatory Safety Constraints

Use of Florina is strictly contraindicated in individuals with certain high-risk conditions, which are explicitly defined in the official label to prevent serious cardiovascular events. These conditions include a current or past history of VTE/ATE, uncontrolled high blood pressure, diabetes with vascular damage, severe liver disease or liver tumors, and specific types of migraines (especially those with aura, or any migraine in women over age 35 who smoke). Furthermore, the risk of VTE is noted to be highest during the first year of use and when restarting the medicine after a break of four weeks or longer, while irregular bleeding is more common during the first three months of use.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory guidance for overdosage of Florina (Ethinyl Estradiol and Levonorgestrel) is documented by government health authorities, and the presentation is primarily based on the expected hormonal effects. According to official regulatory statements, overdosage is generally not expected to be life-threatening.

Documented Clinical Manifestations

The most commonly documented clinical manifestations listed in the official prescribing information relate to gastrointestinal and reproductive systems:

  • Nausea and vomiting.
  • Withdrawal bleeding, which may present as heavy vaginal bleeding due to the hormonal composition.

Mandated Emergency Actions

The regulatory documents emphasize immediate action due to the requirement for supportive care:

  • Seek immediate medical attention upon suspicion of overdosage.
  • Contact a Poison Control Center for immediate guidance is required.

Supportive Care and Population Note

Management is guided by the fact that no specific antidote is known for this product. Consequently, treatment is restricted to symptomatic and supportive care. This management may involve observation and monitoring as clinically appropriate. A population-specific consideration noted in the regulatory label is that overdosage in a pre-pubescent female patient may cause withdrawal bleeding prior to the onset of menarche.

Therapeutic Uses of Florina

What Florina Treats: Main Uses and Benefits

The core therapeutic application of Florina is used to help with the management of pregnancy risk, and is considered relevant as a form of contraceptive support. Therapeutic applications are applicable within clinical settings that involve recurrent or disruptive symptom patterns, and are applied across domains where additional symptomatic support is needed.

The medication is commonly used to help manage several categories of symptoms and conditions. This includes providing symptomatic relief for women with dysmenorrhea (symptoms related to physical discomfort) and assists with maintaining functional stability regarding menstrual cycles. It also is relevant for easing symptoms related to systemic imbalance (heavy blood loss), and offers supportive relief for moderate acne vulgaris associated with hormonal fluctuations.

“The use of this medication assists with maintaining functional stability and supports patients during episodes of heightened discomfort that often accompany the menstrual cycle.”

It is applied across domains where additional symptomatic support is needed, contributing to improved comfort during symptomatic periods.


Quick Fact: Relevant for Symptoms that Interfere with Daily Functioning

Florina is commonly applied to help ease the overall symptom load associated with conditions characterized by periods of heightened symptoms, such as severe menstrual cramping and cycle irregularity.


Regulatory References

  1. NIH MedlinePlus overview of oral contraceptives

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Females of reproductive potential (post-menarche).

Populations for whom use is not recommended (if applicable):

  • Lactating (Breastfeeding) women or women less than four weeks after delivery (postpartum period), due to increased risk of thromboembolic disease.

Populations for whom use is contraindicated:

  • Women over 35 years of age who smoke.
  • Individuals with a high risk of arterial or venous thrombotic diseases, including a current or past history of Deep Vein Thrombosis, Pulmonary Embolism, Stroke, or Myocardial Infarction.
  • Current or history of breast cancer or other known or suspected hormone-sensitive cancer.
  • Current diagnosis of, or history of, liver tumors, severe (decompensated) cirrhosis, or acute viral hepatitis.
  • Women with uncontrolled hypertension or diabetes mellitus with vascular disease.
  • Women with migraine headaches with aura.
  • Known or suspected pregnancy.

Age-Related and Condition-Specific Eligibility

  • Pediatric Use: Not indicated for use before menarche (first menstrual period).
  • Geriatric Use: Not indicated for use in postmenopausal women.
  • Hepatic Impairment: Contraindicated in severe liver disease. Discontinuation is required if jaundice or acute liver test abnormalities develop.

Eligibility-Related Restrictions

  • Major Surgery/Immobilization: Must be discontinued at least four weeks prior to and for two weeks after major surgery or during prolonged immobilization due to the risk of thromboembolism.

Connection to the overall eligibility profile: Official regulatory documents strictly define who can and cannot use Florina by establishing absolute exclusions (contraindications) based on the drug's potential to exacerbate high-risk pre-existing conditions, particularly those involving thromboembolic and vascular risk. Use is officially limited to females of reproductive potential and is subject to cessation requirements during periods of heightened thrombotic risk (e.g., surgery, postpartum) as defined in the regulatory label.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the product's interaction profile across several domains, primarily involving pharmacokinetic effects that can alter the concentration of the hormones in Florina or the co-administered drug.

Interaction Domain Example Interacting Medicinal Products/Classes
Enzyme-Inducing Agents Anticonvulsants (e.g., Carbamazepine, Phenytoin), Griseofulvin, Rifampicin, St. John's Wort
Hepatitis C Combinations Ombitasvir/paritaprevir/ritonavir (with or without Dasabuvir)
Other Drugs Tranexamic Acid, Lamotrigine, Warfarin, Corticosteroids (e.g., Prednisolone)

Co-administration with enzyme-inducing agents, which increase the breakdown of the hormonal components via hepatic cytochrome P450 enzymes, can result in reduced effectiveness of Florina. This requires the use of additional or alternative non-hormonal contraception during and for a period after the use of the enzyme inducer.

Conversely, the use of Florina is contraindicated with certain drug regimens for Hepatitis C (specifically ombitasvir/paritaprevir/ritonavir, with or without dasabuvir) due to the risk of clinically significant elevations in liver enzymes (ALT). The product may also affect the action of other drugs; for instance, it can increase the exposure of corticosteroids and Tranexamic Acid, while decreasing the exposure of Lamotrigine. For procedures, official documents require that Florina be discontinued before and for a set period after major surgery or during prolonged immobilization, due to an increased risk of thromboembolism.

Mechanism of Action

How Florina Works: Mechanism of Action

The mechanism of Florina involves the coordinated engagement of two synthetic hormones, Ethinyl Estradiol and Levonorgestrel, across three primary mechanistic domains which establishes multiple physiological barriers to conception.


Central Suppression of the Endocrine Axis

This domain involves the drug's activity as an agonist at the Estrogen and Progesterone Receptors within the hypothalamus and pituitary gland. This receptor activation reinforces the body's natural negative feedback loop, leading to the suppression of Gonadotropin-releasing hormone ( GnRH), Follicle-Stimulating Hormone (FSH), and Luteinizing Hormone (LH). The resulting physiological effect is anovulation, the failure of the ovary to develop and release an egg.


Physicochemical Barrier Formation

This mechanism is driven by the local, tissue-level effects of the Levonorgestrel component on the female reproductive tract. By acting on the cervical glands, the drug causes the mucus to become highly viscous and thick, creating a physical barrier that restricts the movement and passage of sperm into the upper reproductive tract.


Endometrial Inactivation

The third mechanistic domain involves modulating the cyclical growth and preparation of the uterine lining. The sustained presence of synthetic progestin and estrogen induces an atrophic and inactive endometrium that is prematurely arrested in its development. This physiological state results in an endometrial state that does not support implantation.

Dosage and Administration Information

Topical Administration Instructions

Florina, which may contain the corticosteroid fluocinolone acetonide, is for external use on the skin only. Use this medication exactly as prescribed by your healthcare provider; do not use more, more often, or for a longer duration than instructed to avoid potential adverse effects and skin irritation.

Application Steps

  1. Wash and dry your hands thoroughly before and after applying the medication, unless you are treating your hands.
  2. Apply a small amount of the preparation (cream, ointment, or solution) as a thin, even film to cover the affected area, then rub it in gently.
  3. Avoid contact with the eyes, mouth, and nose. If accidental contact occurs, rinse the area immediately with plenty of water.
  4. Do not use on the face, groin, or underarms unless explicitly directed by a physician, as these areas may be more susceptible to local adverse reactions such as skin atrophy.
  5. The treated area should not be bandaged, covered, or wrapped in a manner that creates an occlusive (airtight) dressing unless your doctor has specifically directed this, as occlusion significantly increases systemic absorption.

Special Considerations

  • Do not use this medication for any condition other than the one for which it was prescribed. Report any signs of local adverse reactions, or if your condition does not improve within two weeks, to your physician.
  • Parents of pediatric patients should avoid using tight-fitting diapers or plastic pants on a child treated in the diaper area, as these act as occlusive dressings.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Florina

Florina is a combined oral contraceptive (COC) that contains Ethinyl Estradiol and Levonorgestrel. The research evidence for this combination was studied for contraception, as well as its evaluated effects on certain common conditions that are linked to the menstrual cycle. The studies summarized here describe group patterns and contribute to the broader evidence landscape.


Evidence for Use in Preventing Pregnancy (Contraception)

The research base for this combined formulation in the prevention of pregnancy includes large-scale studies, such as both non-blinded and comparative Randomized Controlled Trials (RCTs), supplemented by long-term Observational Cohort Studies. Researchers primarily measured Contraceptive Efficacy, commonly quantified by the Pearl Index (the number of unintended pregnancies that occur per 100 woman-years of use). Studies reported measurements of pregnancy rates in these populations and outcomes related to reproductive cycle activity.

Research acknowledges that efficacy outcomes are dependent on user adherence (following the study protocol for use), and research explores how real-world use may differ from optimal trial conditions. Furthermore, multi-year Post-marketing Surveillance monitors long-latency events, meaning long-term effects are not fully established from the initial trials alone.


Evidence for Management of Menstrual Cramping (Dysmenorrhea)

Research explored cohorts of individuals with primary dysmenorrhea, which involves conditions characterized by physical discomfort during the menstrual cycle. Research included Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. The studies monitored outcomes related to physical discomfort and functional imbalance.

Findings describe patterns observed where research highlights changes measured during the study period related to pain severity scores and the need for additional pain-relieving medication use. Follow-up durations were typically limited, so there is limited information for long-term outcomes regarding changes in dysmenorrhea symptoms.


Evidence for Support in Moderate Acne Vulgaris

Research explored the use of this combined hormonal product in individuals with moderate acne vulgaris, studied in Randomized, Double-Blind, Placebo-Controlled Trials. Researchers examined outcomes linked to inflammatory or irritative states on the skin, including changes in the count of acne lesions and scores on the Clinician Global Assessment.

The findings describe patterns where studies reported measurements of differences in the count of inflammatory lesions and assessment scores between groups observed. Long-term outcomes related to sustained dermatological changes or recurrence patterns are not fully established. Comparative evidence is lacking in direct, head-to-head research against all other hormonal therapies approved for acne.


What is Still Uncertain in the Research Landscape

The overall body of evidence highlights that findings describe group patterns observed in studies, but results apply only to the populations studied. Specific areas where evidence is limited include: the long-term effects on certain patient-reported outcomes describing perceived discomfort beyond the initial study window; comparative evidence against every other approved combined oral contraceptive for the purposes of other conditions studied; and subgroup findings for women with specific pre-existing conditions.

Key Studies & References

  1. Oral Contraceptive Pills - StatPearls - NCBI Bookshelf

Frequently Asked Questions (FAQ)

Common questions about Florina (FAQ)


Q: Can Florina cause long-term side effects?

A: Regulatory documents indicate that the use of Florina is associated with serious side effects, such as thromboembolic events (like blood clots) and liver tumors. The risk of venous thromboembolism (VTE) is noted to be highest during the first year of use. These potential effects are monitored by regulatory bodies.


Q: Can Florina be taken if I have a history of [common organ] problems?

A: Official guidelines state that Florina is contraindicated for individuals with conditions like uncontrolled high blood pressure, severe liver disease, or diabetes with vascular damage. Regulatory documents indicate the drug is generally used cautiously in the presence of renal (kidney) dysfunction. The product label defines the specific health history restrictions.


Q: Is it possible for Florina to stop working after a while?

A: Official product information indicates that the contraceptive effectiveness of Florina can be reduced when taken alongside certain drugs. This occurs if co-administered drugs cause an increase in the breakdown of the hormones by liver enzymes. When this happens, official guidance describes the necessity of using additional, non-hormonal methods of contraception.


Q: Can I take Florina if I am taking herbal supplements?

A: Official regulatory documents specifically identify the herbal product St. John's Wort as one that may reduce the effectiveness of oral contraceptives like Florina. If St. John's Wort is used, official guidance describes the necessity of using alternative or additional contraception methods.


Q: What population groups were included in the main clinical trials for Florina?

A: The main clinical trials included cohorts of females of reproductive potential who were evaluated for contraception efficacy. Specific studies also assessed use in subgroups with conditions like moderate acne and primary dysmenorrhea (menstrual cramping). Official documents also define specific contraindications based on age, smoking status, and vascular risk.


Q: If Florina causes a certain side effect, does it usually go away?

A: Official information notes that irregular uterine bleeding, such as spotting or breakthrough bleeding, is typically more common when first starting Florina. This effect is noted to occur most often during the first three months of use.


Q: Does Florina interact with common over-the-counter pain relievers?

A: The Ethinyl Estradiol component in Florina may decrease or delay the effects of the common over-the-counter pain reliever acetaminophen. Official information suggests that using both drugs at typical doses does not result in significant additional risk.


Q: Is it true that Florina can affect my sleep?

A: Some product information listings mention that feelings of tiredness or sleepiness are possible side effects. These effects may also be associated with symptoms reported in the context of overdose.


Q: How long does it usually take to feel the effects of Florina?

A: For contraceptive purposes, official guidance indicates that effectiveness is typically achieved after taking the 8th active tablet. Depending on when use is initiated, a second (backup) method of contraception is described in the official instructions for the first seven days.


Q: Are there any major food or drink restrictions when taking Florina?

A: Regulatory information notes that consuming grapefruit or grapefruit juice may potentially increase the blood levels of the Levonorgestrel component of Florina. Official information indicates that monitoring may be considered for patients who regularly consume grapefruit.


Q: What should I do if I miss a dose of Florina?

A: The official patient information included with Florina provides specific, detailed instructions for handling missed doses. These instructions outline which steps to take, including when a backup contraceptive method is required if doses are missed.


Q: Is Florina considered a long-term treatment option?

A: Official guidance indicates that treatment may be continued for as long as the contraceptive method is desired and is well tolerated by the individual. No specific maximum duration of use is generally cited in official documents.


Q: What is the typical timeframe for seeing the full benefits of Florina?

A: Contraceptive effectiveness is typically reached after taking the 8th active tablet. The time to realize the full benefit for other uses, like acne or dysmenorrhea, may vary based on clinical study findings.


Q: Does Florina require special blood tests while taking it?

A: Official guidance recommends the monitoring of blood pressure at routine health visits. Blood or urine tests may also be needed to check for certain unwanted effects. Special monitoring of blood glucose is described in the official guidance for patients with diabetes.


Q: Does Florina have a black box warning from the FDA?

A: Yes, the FDA label includes a BOXED WARNING (the most serious warning) regarding the risk of serious cardiovascular events. This warning is particularly emphasized for women over 35 years old who smoke cigarettes.


Q: Is it common to feel tired when starting Florina?

A: Some official product information lists feelings of tiredness, or unusual weakness and fatigue, as possible side effects. These effects may also be associated with symptoms reported in the context of overdose.


Q: How often do people need to take Florina?

A: Official guidance specifies that the drug is to be taken once daily. It is generally described as being taken at the same time each day on a continuous schedule, as defined in the product label.


Q: What happens if Florina is taken with a medicine for high blood pressure?

A: Official documents state that the drug is contraindicated in women with uncontrolled hypertension (high blood pressure). For all users, blood pressure should be monitored at routine visits, as an increase in blood pressure has been reported with use.


Q: Are there any specific lifestyle changes recommended when starting Florina?

A: The official label includes a contraindication for use in women over age 35 who smoke, and contains warnings related to sun exposure. Sun exposure may worsen melasma (dark skin patches), and the label advises using sunscreen or protective clothing.


Q: Do I need to avoid certain vitamins while on Florina?

A: Studies indicate that the Ethinyl Estradiol component may affect the body's levels of certain vitamins, including Vitamin B6, B12, C, and Folic Acid. These changes may require monitoring or supplementation.


Q: Does Florina have an effect on kidney function?

A: Estrogens and progestogens are generally administered cautiously in patients with known renal dysfunction (kidney impairment). Studies have also suggested the drug may alter fluid and electrolyte balance.


Q: Is it possible to be allergic to Florina?

A: Official patient information states that a very serious allergic reaction to Florina is rare but remains possible. Symptoms associated with severe reactions typically include rash, significant itching or swelling (especially of the face/tongue/throat), and trouble breathing.


Q: What kind of monitoring is typically involved when taking Florina?

A: Regulatory guidance describes routine monitoring that may include blood pressure checks. Periodic gynecological examinations, breast self-exams, and specific monitoring of blood glucose for women with diabetes is also described.


Q: What is the maximum duration of use described in official guidelines for Florina?

A: Official guidance generally states that treatment should be continued for as long as the contraceptive method is desired and well tolerated. No specific maximum duration of use is cited in official documents.

How should Florina be stored and disposed of?

How to Store and Dispose of Florina?

The storage and disposal of Florina (Ethinyl Estradiol and Levonorgestrel tablets) must adhere strictly to the conditions specified in official regulatory labeling.

Storage Conditions

The product must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Temporary excursions are permitted between 15 C and 30 C.

The tablets require protection from environmental factors. You must keep from freezing, avoid excessive heat, and store the product away from moisture and direct light.

Packaging and Safety

Florina must be kept in the original container and the container must be tightly closed to preserve the product's stability. All medication must be stored out of the reach and sight of children.

Disposal Instructions

Do not keep outdated medicine or medicine no longer needed. The official method for discarding unused or unwanted Florina is through a drug take-back program. If no take-back option is available, unused tablets should be mixed with an undesirable substance, placed in a sealed bag or container, and disposed of in the household trash as per FDA guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Florina found in:

A-Z Index: